NYSE:MRK

Merck & Co., Inc. Stock Forecast, Price & News

$76.40

+0.82 (+1.08 %)

(As of 06/24/2021 03:04 PM ET)

Add

Compare

Today's Range

$75.61

▼

$76.64

50-Day Range

$72.40

▼

$79.87

52-Week Range

$71.71

▼

$87.80

Volume395,073 shs

Average Volume12.02 million shs

Market Capitalization$193.45 billion

P/E Ratio27.68

Dividend Yield3.41%

Beta0.4

30 days | 90 days | 365 days | Advanced Chart

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases). Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
June 24, 2021 | finance.yahoo.com

Merck's Keytruda Meets Main Endpoints in Cervical-Cancer Study >MRK
June 22, 2021 | marketwatch.com

Gov. Ducey’s decision to block COVID-19 policies for universities is ‘not based in science’: Doctor
June 18, 2021 | finance.yahoo.com

10 Best Healthcare Stocks to Buy According to Hedge Funds
June 17, 2021 | finance.yahoo.com

This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market
June 17, 2021 | finance.yahoo.com

MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
June 17, 2021 | finance.yahoo.com

Merck to Participate in the Guggenheim Biopharma Strategy Series
June 17, 2021 | finance.yahoo.com

Merck & Co., Inc. (NYSE:MRK) Sees Strong Trading Volume
June 16, 2021 | americanbankingnews.com

Is Merck & Co., Inc. (MRK) Going to Burn These Hedge Funds?
June 14, 2021 | finance.yahoo.com

$1.58 EPS Expected for Merck & Co., Inc. (NYSE:MRK) This Quarter
June 13, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:MRK
Previous Symbol
CUSIP58933Y10
CIK310158
Webwww.merck.com
Phone908-740-4000
Employees74,000
Year Founded1891

Sales & Book Value

Annual Sales$47.99 billion
Price / Sales4.03
Cash Flow$7.41 per share
Price / Cash Flow10.31
Book Value$10.04 per share
Price / Book7.61

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares2,532,058,000
Market Cap$193.45 billion
Next Earnings Date7/29/2021 (Confirmed)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

2.26 out of 5 stars

Medical Sector

23rd out of 2,105 stocks

Pharmaceutical Preparations Industry

11th out of 832 stocks

3.4 Analyst's Opinion

Consensus Rating
Merck & Co., Inc. has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $97.00, Merck & Co., Inc. has a forecasted upside of 26.9% from its current price of $76.46.
Amount of Analyst Coverage
Merck & Co., Inc. has only been the subject of 4 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Merck & Co., Inc. has received 872 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Merck & Co., Inc. has received 841 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Merck & Co., Inc. has received 50.90% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote “Outperform” if you believe MRK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Merck & Co., Inc. pays a meaningful dividend of 3.41%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Merck & Co., Inc. has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Merck & Co., Inc. is 43.77%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 38.35% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck & Co., Inc. insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,513,456.00 in company stock.
Percentage Held by Insiders
Only 0.32% of the stock of Merck & Co., Inc. is held by insiders.
Percentage Held by Institutions
71.98% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Merck & Co., Inc. are expected to grow by 4.79% in the coming year, from $6.47 to $6.78 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merck & Co., Inc. is 27.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.38.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merck & Co., Inc. is 27.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 44.66.
Price to Earnings Growth Ratio
Merck & Co., Inc. has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Merck & Co., Inc. has a P/B Ratio of 7.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

What stocks does MarketBeat like better than Merck & Co., Inc.?

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Merck & Co., Inc..

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, July 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings results on Thursday, April, 29th. The company reported $1.40 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.63 by $0.23. The business had revenue of $12.08 billion for the quarter, compared to analysts' expectations of $12.71 billion. Merck & Co., Inc. had a net margin of 14.64% and a trailing twelve-month return on equity of 54.15%. The company's revenue was up .2% on a year-over-year basis. During the same quarter last year, the company posted $1.50 EPS.
View Merck & Co., Inc.'s earnings history.

How has Merck & Co., Inc.'s stock price been impacted by Coronavirus (COVID-19)?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MRK stock has decreased by 3.7% and is now trading at $76.34.
View which stocks have been most impacted by COVID-19.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a dividend on Tuesday, June 1st. Stockholders of record on Friday, June 4th will be given a dividend of $0.65 per share on Wednesday, June 2nd. This represents a yield of 3.42%. The ex-dividend date is Thursday, June 3rd.
View Merck & Co., Inc.'s dividend history.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.41%. Merck & Co., Inc. does not yet have a strong track record of dividend growth. The dividend payout ratio of Merck & Co., Inc. is 43.77%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 38.35% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2021 earnings guidance on Thursday, May, 6th. The company provided EPS guidance of 6.480-6.680 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.570. The company issued revenue guidance of $51.80 billion-$53.80 billion, compared to the consensus revenue estimate of $52.51 billion.

What price target have analysts set for MRK?

11 equities research analysts have issued 1 year price targets for Merck & Co., Inc.'s shares. Their forecasts range from $88.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $97.00 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:

Mr. Kenneth C. Frazier, CEO & Chairman (Age 66, Pay $4.3M)
Mr. Robert M. Davis, Pres (Age 54, Pay $2.29M)
Ms. Jennifer L. Zachary, Exec. VP, Gen. Counsel & Corp. Sec. (Age 43, Pay $1.79M)
Mr. Sanat Chattopadhyay, Exec. VP & Pres of Merck Manufacturing Division (Age 61, Pay $1.56M)
Ms. Caroline Litchfield, Exec. VP & CFO
Mr. David Michael Williams, Chief Information & Digital Officer
Mr. Peter Dannenbaum CFA, VP of Investor Relations
Michael W. Fleming, Sr. VP and Chief Ethics & Compliance Officer (Age 62)
Ms. Jennifer Mauer, VP of Global Communications
Mr. Steven C. Mizell, Exec. VP & Chief HR Officer (Age 61)

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Merck & Co., Inc.'s key competitors?

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of MRK's competitors.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.66%), Geode Capital Management LLC (1.69%), Franklin Resources Inc. (1.40%), Capital International Investors (1.31%), Northern Trust Corp (1.27%) and Bank of New York Mellon Corp (1.21%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Richard R Deluca, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Berkshire Hathaway Inc, Nuveen Asset Management LLC, BlackRock Inc., Brandywine Global Investment Management LLC, TD Asset Management Inc., Bank of Nova Scotia, Capital International Investors, and Schafer Cullen Capital Management Inc. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Robert M Davis, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Arrowstreet Capital Limited Partnership, Massachusetts Financial Services Co. MA, Man Group plc, Cullen Capital Management LLC, Nordea Investment Management AB, Factorial Partners LLC, and Orbimed Advisors LLC.
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $76.34.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $193.30 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $5.94 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 74,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

Where are Merck & Co., Inc.'s headquarters?

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

This page was last updated on 6/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here